TABLE 1.
Characteristics and Pregnancy Outcomes of the Study Population
| Characteristics | n (%) | Median (Range) |
|---|---|---|
| Age (yrs) | 26 | 31.2 (18.6–40.9) |
| Weight at delivery (kg) | 22 | 80.3 (60.5–122) |
| Weight postpartum (kg) | 23 | 77 (54–113) |
| CD4+ at delivery (cells/µL) | 26 | 539 (251–1339) |
| Race/ethnicity | ||
| Black | 11 (42) | — |
| Hispanic | 8 (31) | — |
| White | 6 (23) | — |
| Other | 1 (4) | — |
| Concomitant medications | ||
| Zidovudine + lamivudine | 16 (62) | — |
| Zidovudine + lamivudine + abacavir | 6 (23) | — |
| Other | 4 (15) | — |
| Weeks of ARV treatment before delivery | 26 | — |
| On ARV therapy before pregnancy | 11 (42) | 149 (45–383) |
| Began ARV therapy during pregnancy | 15 (58) | 19 (10–26) |
| Third trimester plasma HIV-1 RNA (copies/mL) | 24 | — |
| Undetectable | 21 (88) | — |
| Detectable | 3 (13) | 520 (79–98,871) |
| Delivery plasma HIV-1 RNA (copies/mL) | 25 | — |
| Undetectable | 22 (88) | — |
| Detectable | 3 (12) | 75 (72–77,068) |
| Postpartum plasma HIV-1 RNA (copies/mL) | 20 | — |
| Undetectable | 17 (85) | — |
| Detectable | 3 (15) | 75 (72–88) |
| Pregnancy outcomes | ||
| Gestational age at delivery (wks) | 26 | 37.6 (35.0–41.7) |
| Birth weight (g) | 26 | 2953 (2135–4207) |